licenses hepatitis C drug to Cipla, Ranbaxy, 5 others
Send a link to a friend
[September 15, 2014] NEW
DELHI/MUMBAI (Reuters) - U.S. drugmaker Gilead Sciences Inc said on
Monday it has licensed its hepatitis C drug to seven companies including
Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91
developing countries including India.
Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd,
Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now
be able to make and sell the Sovaldi generic, the company said in a
The companies will be allowed to set their own prices for the
generic drug, and will pay a royalty on their earned sales to
Gilead, it said.
Gilead's Sovaldi, chemically sofosbuvir, is hailed as a breakthrough
in treating hepatitis C, but the company has come under fire over
its product's $1,000-per-pill price tag in the United States.
(Reporting by Aditya Kalra in NEW DELHI and Zeba Siddiqui in Mumbai;
Editing by Sunil Nair)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column]